40 completed, 30 recruiting, 19 unknown, 10 terminated. 114 Phase 1, 45 Phase 2.
Follow Chemotherapy: new trials by email Literature Review of Chemotherapy trials Research Report on Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer HS-20093, Ivonescimab, Chemotherapy - Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 102 | 2026-11-10 | 2026-10-27 |
| Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer Ubamatamab, Chemotherapy, Bevacizumab - Ovarian Cancer | Phase 1 / Phase 2 | Not yet recruiting | ARCAGY/ GINECO GROUP | 43 | 2026-08-01 | 2026-07-10 |
| Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer Propranolol Hydrochloride, Toripalimab, Chemotherapy - Resectable Non-Small-Cell Lung Cancer | Phase 1 | Recruiting | Second Xiangya Hospital of Central South University | 9 | 2026-06-01 | 2026-10-21 |
| Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer Propranolol Hydrochloride, Adebrelimab, Chemotherapy - Small Cell Lung Cancer (SCLC) | Phase 1 | Recruiting | Second Xiangya Hospital of Central South University | 18 | 2026-05-29 | 2026-10-21 |
| Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma Chemotherapy, Lattice Radiotherapy (LRT) - Oral Cavity Squamous Cell Carcinoma | Phase 1 | Not yet recruiting | NYU Langone Health | 30 | 2026-04-01 | 2026-01-29 |
| A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 KRC-01, External Beam Radiation Therapy, cisplatin - Cervical Cancer | Phase 1 | Recruiting | Kortuc, Inc. | 70 | 2026-03-01 | 2026-04-08 |
| Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer Biospecimen Collection, Chemotherapy, Decitabine - Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 32 | 2026-01-23 | 2026-07-15 |
| Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia Chemotherapy, HLA-mismatched GPBMC infusion, Allogeneic Stem Cell Transplantation - Relapsed Leukemia, Refractory Leukemia | Phase 1 | Recruiting | Beijing 302 Hospital | 5 | 2025-12-01 | 2025-12-22 |
| Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer Entinostat, Chemotherapy - Bladder Cancer, Histone Deacetylase Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 29 | 2025-12-01 | 2025-12-03 |
| PULSAR Combined With Immunotherapy and Chemotherapy Iparomlimab and Tuvonralimab Injection (QL1706), PULSAR - Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Wang Xin | 60 | 2025-11-04 | 2025-12-18 |
| 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY) Retifanlimab, Chemotherapy, 9-ING-41 - Pancreatic Adenocarcinoma | Phase 1 | Recruiting | Anwaar Saeed | 12 | 2025-09-22 | 2026-09-24 |
| A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects Fecal microbiota transplantation (FMT) - Fecal Microbiota Transplantation (FMT), Gastrointestinal Neoplasms | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 90 | 2025-09-01 | 2026-01-06 |
| Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases Chemotherapy, Radiofrequency ablation (RFA), In situ immunotherapy - Unresectable Colorectal Liver Metastases | Phase 1 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 12 | 2025-08-01 | 2025-04-06 |
| Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC Glutathione, PD1 Inhibitor, Chemotherapy - Non-Small Cell Lung Cancer, Chemotherapy | Phase 1 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 80 | 2025-06-01 | 2025-08-07 |
| AK129 Combination Therapy for Advanced Solid Tumors AK129(dose 1), Pemetrexed, Paclitaxel - Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1 / Phase 2 | Recruiting | Akeso | 230 | 2025-05-21 | 2025-06-03 |
| A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer Nivolumab, Chemotherapy, SBRT - Non-Small Cell Lung Cancer | Phase 1 | Recruiting | University of Maryland, Baltimore | 18 | 2025-04-22 | 2026-05-06 |
| Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors QL1706, Chemotherapy - Intermediate Trophoblastic Tumor | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 20 | 2025-04-15 | 2025-04-30 |
| A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors BGB-B455, Chemotherapy - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 90 | 2025-03-18 | 2026-08-24 |
| A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer Oncolytic virus VRT106, Chemotherapy - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 18 | 2025-03-17 | 2025-08-17 |
| A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer Oncolytic virus VRT106, Chemotherapy - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Xiangya Hospital of Central South University | 10 | 2025-03-12 | 2025-03-10 |
Showing 20 of 114. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (15) · Pancreatic Neoplasms (10) · Colorectal Neoplasms (9) · Neoplasms (9) · Ovarian Neoplasms (9) · Glioblastoma (7) · Breast Neoplasms (6) · Leukemia (6) · Leukemia, Myeloid, Acute (6) · Lung Neoplasms (6) · Neoplasm Metastasis (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Squamous Cell Carcinoma of Head and Neck (6) · Stomach Neoplasms (6) · Carcinoma, Ovarian Epithelial (5)
National Cancer Institute (NCI) (7) · BeOne Medicines (3) · Memorial Sloan Kettering Cancer Center (3) · Second Xiangya Hospital of Central South University (3) · Sichuan University (3) · AbbVie (2) · Akeso (2) · BeiGene (2) · Chinese PLA General Hospital (2) · Clinical Oncology Research Associates (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Mayo Clinic (2) · NYU Langone Health (2) · Ningbo Cancer Hospital (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2)
United States (56) · China (47) · France (8) · United Kingdom (7) · Australia (6) · Spain (5) · Netherlands (4) · South Korea (4) · Germany (3) · Italy (3) · Belgium (2) · Japan (2) · New Zealand (2) · Romania (2) · Singapore (2)
Huajun Jin (2) · Jiangtao Wang (2) · Paul Sabbatini, MD (2) · Paul Schwarzenberger, MD (2) · Qijun Qian (2) · You Lu, MD (2) · Adam L. Holtzman, MD (1) · Adrienne C Scheck, PhD (1) · Aminah Jatoi, M.D. (1) · Anwaar Saeed, MD (1)
PMID 39368878, PMID 15131031, PMID 16626792, PMID 17896890, PMID 21436454, PMID 24766732, PMID 25895027, PMID 27191266, PMID 29595064, PMID 31039052, PMID 33674274, PMID 33820822, PMID 34088831, PMID 35293148, PMID 35534566, PMID 37046691, PMID 37689733, PMID 38148327, PMID 38788174, PMID 38830992, PMID 40062648, PMID 40246985, PMID 40266036, PMID 40651363, PMID 40819238, PMID 41289795, PMID 41318814, PMID 42409321
2014 (1), 2016 (1), 2017 (1), 2018 (1), 2023 (1), 2025 (1), P30CA068485 (1), P50CA097257 (1), R01CA109767 (1), R01CA113482 (1), R01CA195473 (1), R01CA273028 (1), R37CA287204 (1)